26CA Stock Overview
A clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
ImmunityBio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.15 |
| 52 Week High | US$9.21 |
| 52 Week Low | US$2.15 |
| Beta | -0.19 |
| 1 Month Change | 36.28% |
| 3 Month Change | -24.98% |
| 1 Year Change | -29.42% |
| 3 Year Change | -51.12% |
| 5 Year Change | n/a |
| Change since IPO | -88.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| 26CA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -3.3% | -2.5% | 2.7% |
| 1Y | -29.4% | -7.1% | 18.1% |
Return vs Industry: 26CA underperformed the German Biotechs industry which returned -7.1% over the past year.
Return vs Market: 26CA underperformed the German Market which returned 18.1% over the past year.
Price Volatility
| 26CA volatility | |
|---|---|
| 26CA Average Weekly Movement | 16.0% |
| Biotechs Industry Average Movement | 5.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 26CA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 26CA's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 672 | Rich Adcock | immunitybio.com |
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company’s platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme.
ImmunityBio, Inc. Fundamentals Summary
| 26CA fundamental statistics | |
|---|---|
| Market cap | €2.32b |
| Earnings (TTM) | -€562.40m |
| Revenue (TTM) | €7.02m |
330.6x
P/S Ratio-4.1x
P/E RatioIs 26CA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 26CA income statement (TTM) | |
|---|---|
| Revenue | US$7.33m |
| Cost of Revenue | US$0 |
| Gross Profit | US$7.33m |
| Other Expenses | US$595.13m |
| Earnings | -US$587.79m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.81 |
| Gross Margin | 100.00% |
| Net Profit Margin | -8,016.83% |
| Debt/Equity Ratio | -131.0% |
How did 26CA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/14 16:56 |
| End of Day Share Price | 2025/02/13 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ImmunityBio, Inc. is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Justin Zelin | BTIG |
| Jason Kolbert | D. Boral Capital LLC. |
| Dingding Shi | Jefferies LLC |